LibyaTuberculosis profile
Population  2016 6.3 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.61 (0.35–0.95) 9.8 (5.6–15)
Mortality (HIV+TB only) 0.025 (0.015–0.038) 0.4 (0.24–0.6)
Incidence  (includes HIV+TB) 2.5 (1.6–3.7) 40 (25–58)
Incidence (HIV+TB only) 0.056 (0.034–0.082) 0.88 (0.55–1.3)
Incidence (MDR/RR-TB)** 0.12 (0.04–0.2) 1.9 (0.63–3.2)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.13 (0.077–0.19) 0.91 (0.53–1.3) 1 (0.61–1.5)
Males 0.15 (0.087–0.21) 1.3 (0.78–1.9) 1.5 (0.87–2.1)
Total 0.28 (0.16–0.39) 2.2 (1.3–3.2) 2.5 (1.6–3.7)
TB case notifications, 2016  
Total cases notified 1 176
Total new and relapse 1 131
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 100%
          - % pulmonary 63%
          - % bacteriologically confirmed among pulmonary 71%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 45% (31–71)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.27 (0.12–0.44)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 25 2%
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  38
(19–57)
Estimated % of TB cases with MDR/RR-TB 4.1% (1.4–6.9) 16% (13–18)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 61% 966
Previously treated cases, excluding relapse, registered in 2015 22% 51
HIV-positive TB cases registered in 2015 29% 49
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-16 Data: www.who.int/tb/data